Insights into potential causes of vascular hyperpermeability in dengue

Andrew Teo1,2*, Caroline Lin Lin Chua3, Po Ying Chia1,4,5, Tsin Wen Yeo1,4,5*

1 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore,
2 Department of Medicine, The Doherty Institute, University of Melbourne, Melbourne, Australia,
3 School of Biosciences, Faculty of Health and Medicine Sciences, Taylor’s University, Subang Jaya, Malaysia,
4 National Centre for Infectious Diseases, Singapore, Singapore,
5 Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore

* andrewcc.teo@ntu.edu.sg (AT); yeotsinwen@ntu.edu.sg (TWY)

Dengue is a mosquito-borne disease caused by dengue virus (DENV), where four serotypes can infect humans. Most DENV infections are self-resolving, but in some individuals, severe dengue characterised by a sudden increase in haematocrit, rapid decrease in platelet counts, and vascular leakage is a complication [1,2]. In severe dengue, a major pathogenic mechanism is a transient increase in vascular permeability resulting in severe plasma leakage (herein referred to vascular hyperpermeability) leading to hypotension, circulatory collapse, and organ dysfunction [1]. The precise mechanism in DENV-associated vascular hyperpermeability is unclear, and several hypotheses including antibody-dependent enhancement (ADE) and “cytokine storm” have been proposed. In ADE, suboptimal DENV neutralising antibodies against a heterologous serotype (in secondary infection) promotes DENV uptake into immunological cells, increasing infection and viral replication that can exacerbate the immune response [3]. Similarly, infected monocytes release excessive amounts of proinflammatory cytokines and, if dysregulated, can lead to “cytokine storm” [4]. In this article, we present current understandings on the potential causes of dengue-associated vascular hyperpermeability, which is a consequence of complex interactions between the virus and the host endothelium immune response.

1. Compromised endothelial glycocalyx integrity contributes to vascular hyperpermeability

The endothelial glycocalyx layer (EGL) is a glycosaminoglycan-rich barrier, 0.5 to 5.0 μm thick, which coats the luminal surface of the endothelium, forming a mesh that acts as a macromolecular sieve across cell–cell junctions. This surface matrix is composed of various proteoglycans tethered to the underlying endothelial cell including transmembrane syndecans and glycosaminoglycans such as heparan sulphate (HS), chondroitin sulphate (CS), and hyaluronic acid (HA) (Fig 1A). Together with bound plasma proteins such as albumin, fibrinogen, and orosomucoid, the EGL forms a physiological barrier between the intravascular compartment and the interstitium, and damage and degradation may increase vascular permeability [5,6].

Recent studies suggest that EGL is compromised during dengue. EGL disruption and hyperpermeability was reported in dengue mouse model [7,8], and, using videomicroscopy, the thinning of the sublingual EGL was observed in dengue patients with vascular hyperpermeability [9]. Furthermore, increased blood levels of HA, syndecan-1 and CS in dengue patients were proportional to disease severity, further suggesting that EGL is damaged in...
clinical disease [5,6,10]. Importantly, EGL degradation has also been linked to coagulation disorders, increased leukocyte adhesion to the endothelium, and fluid extravasation, which are associated with increased plasma leakage [9–11]. The precise mechanisms that trigger the shedding of EGL components in DENV infection remains elusive.

2. Dengue nonstructural protein 1: A mediator of vascular hyperpermeability

DENV nonstructural protein-1 (NS1) is a highly conserved 48-kDa membrane-associated glycoprotein. Interestingly, NS1 is the only nonstructural viral protein secreted by infected host cells [12], and circulating levels of NS1 correlated positively with vascular permeability in vitro and in vivo [5,8,13,14]. However, other clinical studies have not shown a correlation between...
NS-1-induced vascular permeability. These highlight the complexity of DENV-mediated vascular pathologies and differences in in vitro NS-1 quantification, and the timing of sampling likely contributed to the discrepancies [14–17]. Recent in vitro studies have demonstrated that NS1 protein (expressed by all four DENV serotypes) can directly promote the expression and activation of sialidase, cathepsin L, and heparanase, with the latter enzyme subsequently inducing syndecan-1 shedding to cause vascular hyperpermeability [7,8]. This mechanism of EGL breakdown occurred independently of inflammatory mediators [7].

NS1 also interacts with Toll-like receptor (TLR) 4 and induces the production of proinflammatory and vasoactive mediators including cytokines and vascular growth factors, many of which are likely to cause damage to EGL and inducing vascular pathology [18–20]. Two noteworthy molecules induced by NS1 are matrix metalloproteinases (MMPs) produced by leukocytes and macrophage inhibitory factor (MIF) secreted by endothelial cells [13,21]. EGL components such as syndecan-1, syndecan-2, and syndecan-4 can be cleaved by MMP-9, and this process may be further enhanced through MIF. In DENV infection, increased levels of MMP-2, MMP-9, and MIF have been associated with increased risk of dengue severity, and both MMP-9 and MIF were reported to induce vascular hyperpermeability [13,21,22] (Fig 1B). Additionally, NS-1-induced MMP-9 was demonstrated to disrupt junctional adhesion molecules in vitro, which may trigger vascular hyperpermeability [13]. In a murine dengue model, inhibition of MIF abolished NS-1-induced MMP-9 secretion, and this correlated with reduced syndecan-1 shedding, suggesting that MIF is an important factor that mediates vascular pathology in DENV infection [21]. Overall, these studies suggest that specific targeting of DENV-NS1 protein may have therapeutic potential to prevent EGL breakdown.

3. Activated neutrophils contribute to vascular hyperpermeability

Neutrophils are the most abundant leukocytes in the peripheral circulation. In vitro exposure of neutrophils to DENV resulted in the secretion of leukotriene B4, a potent neutrophil chemotactant, suggesting neutrophil recruitment during DENV infection [23]. In an immune profiling study, increased genetic signature of neutrophil-associated transcripts in the early phase of acute dengue was associated with progression towards dengue shock syndrome (DSS), a consequence of vascular hyperpermeability [24]. Similarly, overexpression of genes encoding for several neutrophil granular proteins were observed in DSS cases compared to mild dengue cases, highlighting neutrophils involvement in severe dengue [25]. Neutrophils are densely packed with potent antimicrobial secretory granules, and stimulation of these immune cells with DENV can cause degranulation and neutrophil extracellular traps (NETs) formation; these were associated with increased vascular permeability (Fig 1C). In dengue patients, a significant increase in the peripheral circulation of canonical proteins that are associated with neutrophil degranulation, and granular proteins such as neutrophil elastase and α-defensin 1 were observed in DSS cases compared to either healthy controls or uncomplicated dengue cases [26–28]. Furthermore, NETs formation (quantified by levels of peripheral MPO-DNA complexes) correlated positively to plasma syndecan-1 levels and plasma leakage, suggesting that degradation of EGL by neutrophils may contribute to vascular hyperpermeability [29]. In a mouse model, simultaneous inhibition of C-type lectin domain family 5 member A (CLEC5A, a pattern recognition receptor) and TLR 2, receptors involved in mediating neutrophil activation and NETs formation, significantly reduced vascular permeability and improved survival [30].

Despite much evidence linking activated neutrophils to vascular hyperpermeability, our current understanding on the roles of these immune cells in dengue, whether protective or pathological, is still limited. Previously, research on neutrophil functions in dengue has not
been prioritised; this is potentially due to reports of neutropenia in DENV-infected patients [31]. However, emerging data strongly suggest that neutrophils are not merely bystanders during DENV infection, and future studies investigating the neutrophils-EGL axis in dengue-associated vascular leakage are needed.

4. Activated mast cells contribute to vascular hyperpermeability

Mast cells (MCs) are tissue-resident cells that are present at close proximity to the blood vessels. They have numerous cytoplasmic secretory granules that contain many inflammatory mediators including vasoactive molecules (Fig 1C). Like neutrophils, DENV stimulates MCs, and, upon activation, they will degranulate and release mediators such as chymase and tryptase; both enzymes have been shown to induce vascular permeability in vitro and in vivo [32,33]. Additionally, it was proposed that MC degranulation can be triggered by DENV-specific IgG interactions with FcγR, and this was associated with vascular hyperpermeability in mice [34]. Clinically, increased peripheral levels of chymase and tryptase were associated with vascular hyperpermeability compared to nonsevere dengue cases, and tryptase may be a more potent inducer of endothelial damage [32,33,35]. Vascular permeability was greatly reduced in MC-deficient mice compared with MC-replete controls, and drugs that stabilised MCs were observed to limit vascular leakage in DENV-infected mice [32,33]. Of clinical importance, nafamostat mesylate, a tryptase inhibitor, had a significant therapeutic effect in decreasing vascular hyperpermeability in DENV-infected mice, raising the possibility of it being an effective treatment for humans [32].

5. DENV-activated platelets contribute to vascular hyperpermeability

Platelets are small anucleated blood cells that are pivotal in maintaining vascular haemostasis. Interestingly, activated platelets and extracellular vesicles (EVs), released by DENV-activated platelets, can increase vascular permeability (Fig 1C) [36]. NS-1 was shown to activate platelets through TLR4, and knockout of TLR4 attenuated haemorrhaging in DENV-infected mice [37]. Furthermore, DENV can also activate platelets though C-type lectin-like receptors-2, which triggers the release of EVs. These EVs coactivate CLEC5A and TLR2 on neutrophils, inducing NETs formation that correlated with vascular hyperpermeability in mice [30]. DENV-induced EVs also enhance TNF-α secretion, another major mediator of vascular permeability [4]. In vitro, platelets incubated with both NS1 and neutrophils were more potent inducers of NETs formation, compared to stimulation with either NS1 or neutrophils alone [29]. Furthermore, cell-free histone H2A released from neutrophils has also been found to be increased in dengue patients, and H2A can increase platelet activation in vitro [38]. Whether activated platelets and their mediators directly contribute to vascular permeability is unknown, but evidence suggest a complex interaction with neutrophil and other immune cells to promote inflammation-associated vascular hyperpermeability [30,39].

6. Conclusions

Annually, approximately 390 million cases of DENV infections occur with approximately 96 million cases clinically symptomatic [40]. Dengue transmission may further increase due to a warmer climate globally in the coming decades. Currently, many of the mechanisms linking EGL, neutrophils, MC, and activated platelets to increased vascular permeability remain hypothetical, and more research are needed. EGL disruption affects vascular permeability, and therapeutic approaches to attenuate EGL degradation or enhance its synthesis should be explored. Neutrophils and MCs may serve a protective role during early DENV infection, but excess
release of their mediators may cause immunopathology [26,33,41]. Activated platelets and EV may interact with various immunological cells to enhance inflammation, antibodies to disrupt these interactions may be useful in attenuating vascular pathologies observed. Delineation of the mechanisms that compromise glycocalyx integrity is required for rational development of targeted therapies to counteract the pathological responses of these immune cells in DENV infection.

References

1. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. 2009.
2. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine. 2011; 29(42):7221–8. https://doi.org/10.1016/j.vaccine.2011.07.022 PMID: 21781999
3. Shukla R, Ramasamy V, Shannugam RK, Ahuja R, Khanna N. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Front Cell Infect Microbiol. 2020; 10:597. https://doi.org/10.3389/fcimb.2020.572681 PMID: 33194810
4. Malavige GN, Ogg GS. Pathogenesis of vascular leak in dengue virus infection. Immunology. 2017; 151(3):261–9. https://doi.org/10.1111/imn.12748 PMID: 28437586
5. Lin CY, Koliopoulos C, Huang CH, Tenhunen J, Heldin CH, Chen YH, et al. High levels of serum hyaluronan is an early predictor of dengue warning signs and perturbs vascular integrity. EBioMedicine. 2019; 48:425–41. https://doi.org/10.1016/j.ebiom.2019.09.014 PMID: 31526718
6. Tang TH, Alonso S, Ng LF, Thein TL, Pang VJ, Leo YS, et al. Increased Serum Hyaluronic Acid and Heparan Sulfate in Dengue Fever: Association with Plasma Leakage and Disease Severity. Sci Rep. 2017; 7:46191. https://doi.org/10.1038/srep46191 PMID: 28393899
7. Glasner DR, Ratnasiri K, Puerta-Guardo H, Espinosa DA, Beatty PR, Harris E. Dengue virus NS1 cyto-kine-independent vascular leak is dependent on endothelial glycocalyx components. PLoS Pathog. 2017; 13(11):e1006673. https://doi.org/10.1371/journal.ppat.1006673 PMID: 29121099
8. Puerta-Guardo H, Glasner DR, Harris E. Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability. PLoS Pathog. 2016; 12(7):e1005738. https://doi.org/10.1371/journal.ppat.1005738 PMID: 27416066
9. Lam PK, McBride A, Le DHT, Huynh TT, Vink H, Wills B, et al. Visual and Biochemical Evidence of Glycocalyx Disruption in Human Dengue Infection, and Association With Plasma Leakage Severity. Front Med. 2020; 7:545813.
10. Suwarto S, Sasmono RT, Sinto R, Ibrahim E, Suryamin M. Association of Endothelial Glycocalyx and Tight and Adherens Junctions With Severity of Plasma Leakage in Dengue Infection. J Infect Dis. 2017; 215(6):982–9. https://doi.org/10.1093/infdis/jix041 PMID: 28543844
11. Weinbaum S, Cancel LM, Fu BM, Tarbell JM. The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases. Cardiovasc Eng Technol. 2020;1–35. https://doi.org/10.1007/s13239-020-00485-9 PMID: 32959164
12. Gutsche I, Coulibaly F, Voss JE, Salmon J, d’Alayer J, Ermonval M, et al. Secreted dengue virus non-structural protein NS1 is an atypical barrel-shaped high-density lipoprotein. Proc Natl Acad Sci U S A. 2011; 108(19):8003–8. https://doi.org/10.1073/pnas.1017338106 PMID: 21518917
13. Pan P, Li G, Shen M, Yu Z, Ge W, Lao Z, et al. DENV NS1 and MMP-9 cooperate to induce vascular leakage by altering endothelial cell adhesion and tight junction. PLoS Pathog. 2021; 17(7):e1008603. https://doi.org/10.1371/journal.ppat.1008603 PMID: 34310658
14. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis. 2002; 186(8):1165–8. https://doi.org/10.1086/343813 PMID: 12355369
15. Soe HJ, Manikam R, Raju CS, Khan MA, Sekaran SD. Correlation of host inflammatory cytokines and immune-related metabolites, but not viral NS1 protein, with disease severity of dengue virus infection. PLoS ONE. 2020; 15(8):e0237141. https://doi.org/10.1371/journal.pone.0237141 PMID: 32764789
16. Alfonso D, Meneses MD, Fernandes CA, Ferreira DF, Mohana-Borges R. Assessing positivity and circulating levels of NS1 in samples from a 2012 dengue outbreak in Rio de Janeiro, Brazil. PLoS ONE. 2014; 9(11):e113634. https://doi.org/10.1371/journal.pone.0113634 PMID: 25412084
17. Young PR, Hilditch PA, Bletchly C, Halloran W. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol. 2000; 38(3):1053–7. https://doi.org/10.1128/JCM.38.3.1053-1057.2000 PMID: 10698995
18. Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The Good, the Bad, and the Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis. Annu Rev Virol. 2018; 5(1):227–53.

19. Singh S, Anupriya MG, Modak A, Sreekumar E. Dengue virus or NS1 protein induces trans-endothelial cell permeability associated with VE-Cadherin and RhoA phosphorylation in HMEC-1 cells preventable by Angiopoietin-1. J Gen Virol. 2018; 99(12):1658–70. https://doi.org/10.1099/jgv.0.001163 PMID: 30355397

20. Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med. 2015; 7(304):304ra142. https://doi.org/10.1126/scitranslmed.aaa3863 PMID: 26355031

21. Chen HR, Chao CH, Liu CC, Ho TS, Tsai HP, Perng GC, et al. Macrophage migration inhibitory factor is critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability. PLoS Pathog. 2018; 14(4):e1007033. https://doi.org/10.1371/journal.ppat.1007033 PMID: 29702887

22. Her Z, Kam YW, Gan VC, Lee B, Thein TL, Tan JJ, et al. Severity of Plasma Leakage Is Associated With High Levels of Interferon-γ-Inducible Protein 10, Hepatocyte Growth Factor, Matrix Metalloproteinase 2 (MMP-2), and MMP-9 During Dengue Virus Infection. J Infect Dis. 2017; 215(1):42–51. https://doi.org/10.1093/infdis/jiw494 PMID: 28077582

23. Loke WM, Chow AY, Lam Mok Sing K, Lim EC, et al. Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection. Virol J. 2013; 10(322):322. https://doi.org/10.1186/1743-4221-10-322 PMID: 24168271

24. Devignot S, Sapet C, Duong V, Bergon A, Rihet P, Ong S, et al. Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome in Vietnamese children and young adults. J Virol. 2010; 84(24):12982–94. https://doi.org/10.1128/JVI.01224-10 PMID: 20943917

25. Sung PS, Huang TF, Hsieh SL. Extracellular vesicles from CLEC2-activated platelets enhance dengue virus infectivity. J Pathog. 2018; 14(4):e1007033. https://doi.org/10.1371/journal.ppat.1007033 PMID: 29702887
36. Hottz ED, Lopes JF, Freitas C, Valls-de-Souza R, Oliveira MF, Bozza MT, et al. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood. 2013; 122(20):3405–14. https://doi.org/10.1182/blood-2013-05-504449 PMID: 24009231

37. Chao CH, Wu WC, Lai YC, Tsai PJ, Perng GC, Lin YS, et al. Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage. PLoS Pathog. 2019; 15(4):e1007625. https://doi.org/10.1371/journal.ppat.1007625 PMID: 31009511

38. Trugilho MRO, Hottz ED, Brunoro GVF, Teixeira-Ferreira A, Carvalho PC, Salazar GA, et al. Platelet proteome reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue. PLoS Pathog. 2017; 13(5):e1006385. https://doi.org/10.1371/journal.ppat.1006385 PMID: 28542641

39. Hottz ED, Medeiros-de-Moraes IM, Vieira-de-Abreu A, de Assis EF, Vals-de-Souza R, Castro-Faria-Neto HC, et al. Platelet activation and apoptosis modulate monocyte inflammatory responses in dengue. J Immunol. 2014; 193(4):1864–72. https://doi.org/10.4049/jimmunol.1400091 PMID: 25015827

40. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013; 496(7446):504–7. https://doi.org/10.1038/nature12060 PMID: 23563266

41. Chu YT, Wan SW, Anderson R, Lin YS. Mast cell-macrophage dynamics in modulation of dengue virus infection in skin. Immunology. 2015; 146(1):163–72. https://doi.org/10.1111/imm.12492 PMID: 26059780